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Studiesofplatinum drug-DNAadductformation intissuesofcancer patientshave involved both atomicabsorbance
spectroscopy (AAS), which measurestotalDNA-bound platinum, andanti-cisplatin-DNA enzyme-linked immunosor-
bent assay (ELUSA), which detects a fraction ofthe AAS-measurable adduct. These studies were designed to explore
mechanismsofdrug-DNAinteractions, tomakecorrelationswithclinical outcome, andpossibly tovalidateDNAadduct
measurementsfor useinoccupationalandenvironmentalbioHmoitoring.The resls, determinedbybothELISAandAAS,
demonstrate that cisplatin and its analog carboplatin bind to DNA in many human organs, including kidney, brain,
peripheral nerve,andbone marrow, which aresitesfordrugticity. Platinumwasalsoobservedboundtoovariantumor
DNA. Theadducts werehighly persistent, beingmeasurableintissuesobtainedatautopsy upto15monthsafterthelast
administrationofplatinumchemotherapy. Acomparisonofbood cellDNAadduct levels, determinedbyELISA,andthe
clinical response of139patients withovarian, testicular, colon, orbreast cancerdemonstrated astrongcorrelation be-
tween failuretoform DNAadductsand failureoftherapy. Conversely, patientswho formed high levelsofDNA adduct
weremostlikelytorespondfavorably. AsimilarcorrelationwasnotobservedforadductsdeterminedbyAAS;thatis,the
averagetotalDNA-boundplatinum levels werethe sameforpatientswhodidnotrespondtotherapyandforpatientswho
had any kindofresponse. Thus, inthisstudy, humanbloodcell DNAadductsmeasuredbyELISAcorrelatewith tumor
remission, while those measured by AAS do not.
Introduction
A numberofeffectiveanticancerdrugs areknown todamage
DNA, and their selective cytotoxicities for neoplastic cells are
presumably related to anincreased sensitivity oftumorcells as
compared to normal cells. Newly developed assays have made
it possible to monitor the binding of drugs such as 8-
methoxypsoralen (1), procarbazine (2), mitomycinC (3), and
cisplatin (cis-diamminedichloroplatinum II) (4)boundto DNA
intissuesofcancerpatientsreceivingchemotherapy. Whilesuch
studies are directed toward determining the biologically effec-
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tivedoseofdrugtotargettissueandcorrelating tumorresponse,
they also serve to validateassays for DNA adductformation in
humans, whicharebeingusedforoccupational andenvironmen-
tal biomonitoring (5).
CisplatinbindstoDNAinachemically stablefashiontopro-
duce, primarily, intrastrand bidentate diammineplatinum ad-
ducts by chloridedisplacement atthe N7 positions ofadjacent
guaninesandadenine-guanine (5'-3)dinucleotides (6,7). This
compound, and its cis-reacting analogs such as carboplatin
(diamminecyclobutane-dicarboxylatoplatinum II), are among
the mosteffective drugs curently available for thetreatmentof
testicular, ovarian, lung, and other cancers (8-10). In recent
yearsanumberofhighly sensitiveenzyme-linkedimmunosor-
bent assays (ELISAs) have been developed (4,6) and used to
measurebindingofplatinumdrugstoDNAintissuesofcancer
patients (11,12). In addition, atomic absorbance spectroscopy
(AAS), withtheadditionofZeemanbackgroundcorrection, has
become sufficiently sensitive to measure total platinum bound
to DNA inhuman samples (13).POIRIERETAL.
This paper focuses on platinum drug-DNA interactions in
human tissues. It includes: acomparisonofELISAandAAS for
the determination of cisplatin-DNA adducts in humans; a
demonstration ofwidespread adduct formation and long-term
adduct persistence in human tissues; and a demonstration ofa
positive correlation between adduct formation measured by
cisplatin-DNA ELISA and tumor remission.
Materials and Methods
Clinical Studies
Eight cancer patients studied atautopsy hadbeen treated for
ovarian orbreastcancerorlymphomaonapprovedexperimen-
talprotocolsattheMedicineBranchoftheNationalCancerIn-
stitute (14,15). Each patienthad received one ormore cycles of
chemotherapy containingeithercisplatinorcarboplatinandhad
died 1 dayto 15 monthssincetheirmostrecentplatinumtherapy.
Autopsy was performed within 24 hrofthe time ofdeath, and
samples were taken of bone marrow, lymph nodes, spleen,
kidney, liver, peripheral nerve, andbrain. Fromovarian cancer
patients, samples of the ovarian tumor were obtained. The
medical recordsoftheeightindividuals werereviewedtoobtain
thefollowinginformation: age, gender, causeofdeath, typeand
duration of response to the most recent platinum treatment
regimen, timesince mostrecentplatinumdose, totalcumulative
drug dose, and number ofcourses oftherapy prior to death.
The patients from whom blood was obtained had also been
treated onapproved experimental treatmentprotocols attheNa-
tional CancerInstitute forovarian(14,16), breast(16), colon(16),
ortesticular (17) cancersandhadreceivedeithercisplatinorcar-
boplatin. Multipleprotocols, mostofwhich werecombination
therapies, had been used. Disease response criteria, obtained
from the medical records ofeach patient, were categorized as
follows: progressive disease isa > 25% increaseintumorsize;
stablediseaseisa < 25% changefrombaseline, eitherincrease
or decrease; a minor response is a25-50% decrease in tumor
size; apartial response isa > 50% decrease intumorsize; and
acomplete response is resolutionofallclinicallydetectabledis-
ease. Noresponseisageneric termwhich includesprogressive
and stabledisease and minor response. Blood wasdrawn 24 hr
after the most recent platinum drug infusion.
Isolation ofDNA
All cell pellets and tissues were frozen at -20°C for 1-2
months before DNA preparation. DNA was isolated on CsCl
buoyantdensitygradients, aspreviouslydescribed(18). Thesalt
was removed by dialysis and the DNA content determined by
ultraviolet absorbance at 260 nm.
Cisplatin-DNA ELISA
Thecisplatin-DNA ELISAwasperformedwitharabbitanti-
cisplatin DNA using 35 lAg of DNA per well, as previously
described (4,19). Foreachassay, astandardcurvewasgenerated
usingcalfthymus DNAmodifiedin vitrotoalevelof4.3adducts
per 100nucleotides (determinedbyAAS). The50% inhibition
forthestandardcurvesaveraged 12.9 ± 3.7fmol/pggDNA(mean
+ SD, n = 14). DNA adduct levels were determined for each
biological sampleby comparisonwiththestandardcurveandex-
pressed as attomoles ofadduct per microgram DNA.
Atomic Absorbance Spectroscopy
Total platinum-DNA binding was assessed by AAS with
Zeeman background correction, as previously described (13),
using a Perkin-Elmer Zeeman/3030 atomic absorption spec-
trophotometer. Samplesof200izgDNAwereusedforeachAAS
measurement, andquantification wasdoneby comparison with
a standard curve. Units used are femtomoles of adduct per
microgram DNA.
Results
Comparison ofCisplatin-DNA ELISA and AAS
for Analysis ofDNAAdducts in Human Samples
Whereas AAS measures total platinum bound to DNA, the
cisplatin-DNA ELISA significantly underestimates the total
amountofintrastrand DNAadducts. Thisobservationwas first
madeinsamples fromrats(19,20). AlthoughELISAmeasured
only0.2% ofthetotalDNA-boundplatinumdeterminedbyAAS,
a linear correlation was observed between the two assays in
kidneysofratsexposed toincreasingdosesofthedrug. Asimilar
consistency wasnotfoundinhumansamples(16,19). Inarecent
study in which 197 blood-cell DNA samples were assayed by
bothELISAandAAS, 39samplesgavenegative results inboth
assays, 17 gavepositive results in ELISAonly, 89gavepositive
resultsinAASonly, and52gavepositiveresults inbothassays.
AcomparisonofthevaluesobtainedbyELISAandAASforeach
ofthepositivesamplesisshowninFigure 1. Thefractionoftotal
platinumdetermined inthese52 samplesby ELISAvariedbet-
ween0.2and33% ofthatobservedbyAAS, withalmosthalfof
thesamplesfallingintherangeof2-33%. Asimilarrelationship
appears to hold for human tissue obtained at autopsy; nine
samplesgavepositiveresultsinbothassaysand showed similar
inter-assay discrepancies (compareTables 1 and2).
Platinum-DNA Adducts in Human Tissues
Obtained at Autopsy
Althoughblood-cell DNAsamplesarereadilyobtainablefor
analyses ofDNA adducts, they provide no direct information
about the amount ofDNA damage present in the target tissue
(tumor) orinotherorgansthatmaybesitesfortoxicity. Inaddi-
tion, suchstudiestelluslittleaboutplatinum-DNAadductper-
sistence in specific tissues. Tables 1 and 2 present data on the
tissuesofeightcancerpatientswhohadreceivedtheirlastdoseof
cisplatinorcarboplatinbetweenonedayand 15 monthspriorto
deathandautopsy(15). Thepatientshadeitherlymphoma(patient
1),breastcancer(patient2),orovariancancer(patients3-8). The
tissuesstudiedincludedovariantumor,bonemarrow,lymphnode,
spleen,kidney,liver,peripheralnerve,andbrain.Timesincelast
platinumchemotherapywas7-15monthsforpatients5-8,2and
4monthsforpatients 1and4,respectively,andlessthan 1 month
forpatients2and 3. ItisevidentfromTables 1 and2 thatwide-
spreaddistributionofplatinum-DNAadductsoccursandthatthe
quantitiesofcisplatin-DNAELISA-measurableadductlevelsin
tumoraresimilartothoseseeninothertissues.
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FIGURE 1. Comparison ofvalues obtained by cisplatin-DNA enzyme-linked immunosorbent assay (ELISA) and atomic absorbance spectroscopy (AAS) forthe
same 52 human blood-cell DNA samples.
Table 1. Platinum-DNA adducts(amole/14g DNA) determined by
enzynw-linked immunosorbent assay (ELISA).
Patient number
Tissue 1 2 3 4 5 6 7 8
Tumor __b - 106 58 - 176 73 -
Bone marrow - NDC 100 77 - 141 - -
Lymph node ND 143 - ND - - - -
Spleen 88 343 74 - 141 - 283 113
Kidney - 511 66 50 - 315 122 184
Liver - 457 10 45 211 342 96 78
Peripheral nerve - ND - ND - 62 ND 315
Brain (gray) - 143 122 62 - - - 833
Brain (white) - 306 100 112 - - - 456
'Mean oftwo ELISAs performed on separateoccasions; each assay included
triplicate experimental wells and one control well per sample.
bDash indicates no sample assayed.
'ND, levels below 8amole//Ag DNA, the lowerlimit ofsensitivity.
Table 2. Platinum-DNA adducts (fmole/4gDNA) determined by
atomic absorbance spectroscopy.
Patient number
Tissue 1 2 4 5 6 7
Tumor a - NDb - ND 11
Bone marrow 4 ND ND - - 14
Lymph node 0 28 14 - -
Spleen 14 ND ND 59 - 53
Kidney - 41 6 - 204 38
Liver - 23 29 11 90 198
Peripheral nerve ND ND - 4 19
Brain (gray) - ND 22 - - -
Brain (white) - ND ND
aDash indicates no sample assayed.
hND, levels below 3 fmole/,ug DNA, the lower limit ofsensitivity.
Comparison between Platinum-DNAAdduct
Formation Response in Human Blood Cell DNA
and Disease
Previous determinations ofcisplatin-DNA ELISA-measur-
ableadductsinblood-cell DNAfromovarian(14) andtesticular
(17) cancerpatientsdemonstrated apositivecorrelationbetween
adductsandfavorableclinical outcome (Table3, groups 1 and3).
Intheseinvestigations, one or two samples wereobtained from
each patient, and the highest or "peak" adduct value was con-
sideredforcomparison withdisease response. Clinical response
was categorized as presented in Methods. In a group of24 pa-
tients (Table4) who received single-agentplatinumtherapy, the
correlation between adduct level anddisease response was very
highly significant (p = 0.006) (21). Overall, patients with the
bestclinical responsehadthehighestadduct levels. The studies
are, however, limited to two types of cancer and one assay
procedure.
Recently, theseobservations wererepeated inovarian cancer
patients and extended to breast and colon cancer patients, as
shown in Table 4 (16). The new study has the added advantage
thatmeasurements ofadductsby ELISA werecompared tothose
byAAS forthe samesamples. Thestudycomprised atotalof286
blood samplesobtained from67patients, with 1-2 samplesob-
tainedfrom36% ofpatients, 3-9samples from55% ofpatients
and > 9 samples from 9% ofpatients. Multiple samples were
takenfromeachindividual atintervalsduringtreatment; because
ofsubstantial variation inthenumbersofsamples per person, a
meanadductvalue wascalculatedforeachpatient. Thedatafor
patients grouped by disease response are presented in Table 3
(groups2, 4, and5). Theovarian cancerpatients again showed
astatistically significantcorrelationbetween adduct formation
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lTble 3. Summary ofcomparisons betweencisplatin-DNA adducts measured by enzyme-linked immunosorbent assay and
disease response for 139 cancer patients.
% Complete
Type of and partial Mean (amole/jug DNA)
Group no. Cancer No. ofpatients Pt therapya Priortherapy responders Nonresponderb Respondere p
I Ovarianb 20 SA (+) 33 79 227 0.006
l Ovariane 55 SA + C (+) 58 106 179 0.03
2 Ovarianf 27 C (+) 59 9 61 0.028
3 Testicular"' 17 C (-) 70 (complete) 83 162 0.072
4 Breastf 26 C (+) 11 51 248 0.047
5 Colon' 14 C (+) 21 (partial) 140 223 0.24
'SA, single agent; C, combination.
'The nonresponders in groups 2, 4, and 5 had progressive disease.
'Responders include complete and partial responders. For thebreast and colon cancerpatients, this group also includes individuals with stabledisease, since there
were so few complete and partial responders.
dA subgroup ofthe 55 patients shown in the next group.
eValues are peak or highest adduct level from each individual.
'Values are mean ofseveral adduct levels, determined from DNA samples taken at differenttimes from the same individual.
gThere were no nonresponders, so complete responders were compared to partial responders.
Thble4. Platinum-DNA adductsinblood-cellDNAfrom67cancer patients.
Method ofmeasurementa
Group no. Tumor No. ofpatients ELISA AAS
2 Ovary 27 60 46
4 Breast 26 131 83
5 Colon 14 95 68
Total 67 286 197
'ELISA, enzyme-linked immunosorbent assay; AAS, atomic absorbance
spectroscopy.
and positive clinical outcome. The breast and colon cancer
groups contained fewerresponders, butthetrend fordifferences
in adduct levels between responders and nonresponders were
consistent with those observed for the ovarian and testicular
cancer patients.
Inthis study, itwas possibletomeasuretotalplatinumbound
to DNA by AAS for 197 of the original 286 blood-cell DNA
samples. Figure2 shows acomparisonofthe mean ELISA and
AAS values forpatients withprogressivedisease, compared to
patients witheither stabledisease, partial response, orcomplete
response, grouped together. Analysis by ELISA showed a
statistically significant difference between the two groups, but
analysis by AAS showedsimilaradduct levels forboth groups.
Therefore, inthis study, whenaveragedadductlevels wereused,
high levels ofadduct measured by AAS did not correlate with
tumor remission.
Discussion
Inordertoestablish acisplatin-DNA ELISA, DNAmodified
to4% withcisplatin wasusedtoelicitantiseraspecific forthein-
trastrand bidentate N7-d(GpG)- and N7-d(ApG)-diammine-
platinum adducts. These adducts make up a major portion of
platinum bound to DNA; however, the ELISA developed with
this antiserum provides an underestimate ofthe quantity ofin-
trastrandadductpresent,presumablybecausebiological samples
(1 adduct in 107 nucleotides) have many fewer adducts inprox-
imity thantheoriginal immunogen(1 adductin25nucleotides).
It is possiblethattheantiserum hashighestaffinity forclusters
ofadducts andthatthebindingaffinity isconsiderably reduced
forasingle adduct. Itisalsopossiblethatitisclusters ofadducts
that areprimarily recognized inbiological samples. Inanycase,
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FIGURE 2. Comparison between average platinum-DNA adduct levels
measured by cisplatin-DNA enzyme-linked immunosorbent assay (ELISA)
oratomicabsorbancespectroscopy (AAS), withdiseaseresponse for67 pa-
tients with either ovarian, breast, or colon cancer. Individuals with pro-
gressivedisease (PD; ELISA, n = 23; AAS, n = 20) arecompared tothose
with stable disease (S), partial response (PR) or complete response (CR),
grouped together (ELISA, n = 44; AAS, n =42).
the underestimation obtained with the cisplatin-DNA ELISA
canbecircumventedbyusingAASorbyperformingELISAwith
an antiserum elicited against individual intrastrand adducts
ratherthanmodified DNA(20,22). Thelatterassayhasthedis-
advantagethatsamples mustbecolumnchromatographedprior
to analysis by ELISA, thereby increasing cost and reducing
efficiency.
AcomparisonofresultsobtainedusingAASandthecisplatin-
DNAELISAtoanalyzethesamepatientblood-cellDNAsamples
demonstrated no consistentcorrelation betweenthe two assays
(19). This finding was in contrast to that with rat samples, for
which the two assays exhibited a constant relationship (19).
Human DNA samples have, in general, much more ELISA-
recognizablematerialthanratkidneyDNAsamplesormouseskin
samples. In addition, a much broader range ofinterindividual
variabilityincisplatin-DNAELISA-measurableadductshasbeen
observedinhumancancerpatientsthanininbredrats.
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The data on platinum-DNA adducts in tissues obtained at
autopsyclearlydemonstrate widespreaddistributionandlong-
termpersistenceofbothELISA-andAAS-measurableadducts.
The results show that adducts form in tissues such as kidney,
peripheral nerve, bonemarrowandbrain, whicharesitesofdrug
toxicity, aswellasintumortissue. Thehighdegreeofpersistence
oftheseadducts (14-15 months forpatients 8 and6, respective-
ly) suggests that failure to repair platinum-DNA damage may
contribute tothechemotherapeutic efficacyofthisclassofdrug.
Thecisplatin-DNA ELISAhasbeenusedextensivelytoassay
humanblood-cell andtissueDNA, sincemuchofthisworkwas
performedpriortoourknowledgeoftheunderestimation. Table
3 showstheresultsoftwomajorstudies, involving 139patients,
which demonstrate auniquecorrelationbetweenELISA-meas-
urable adducts and positive clinical outcome. In general, the
absenceofcisplatin-DNAELISA-detectable adductsappears to
beassociatedwithpoordisease response, andpatients whohave
thehighestadductlevelsarethemostlikelytoachieveremission.
The consistency of the correlation (Table 3) strengthens the
evidence foradirectassociationbetweenhighplatinum-DNA
adduct levels and positive disease response.
In contrast, the results ofAAS determinations on the same
samplesshownosimilarcorrelation. ItshouldbenotedthatReed
etal. (23)demonstrated apositivecorrelationbetweendisease
responseandDNAadductsmeasuredbyAAS. Theirstudycom-
prised 21 patients with 15different tumor types who were par-
ticipating in a phase-l trial. The ELISA for Pt-d(GpG) intra-
strand adducts, established with an adduct immunogen rather
than a modified-DNA immunogen, has also been used to in-
vestigate theadduct-disease responsecorrelation (24,25); pre-
liminaryresultswith 11 samples suggestthatthisassaymayalso
show acorrelation. Several laboratories arejustbeginning toex-
amine this correlation; the most extensive data currently
available were obtained with the cisplatin-DNA ELISA.
Conclusions
One goal ofdisease-response correlations is presumably to
predict response in a particular patient. Given human interin-
dividual variability andthefactthatthemosteffectiveregimens
contain acombinationofdrugs, however, itisnotclearthatthis
assay will become auseful tool forpredicting response. It will
nevertheless allow furtherinvestigationoffactorsthatmodulate
platinum-DNA adductformationandcontinuetoenhance our
understanding ofplatinum drug-DNA interactions.
This manuscript was presented at the Conference on Biomonitoring and
Susceptibility Markers in HumanCancer: Applications inMolecularEpidem-
iologyand RiskAssessmentthatwasheld inKailua-Kona, Hawaii, 26October-I
November 1991.
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